Functional 2D Nanoplatforms Alleviate Eosinophilic Chronic Rhinosinusitis by Modulating Eosinophil Extracellular Trap Formation
Advanced Science · 2024
DOI: 10.1002/advs.202307800 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Zhaoxu Tu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, China. Hauptthemen laut MEDLINE: Eosinophilia, Extracellular Traps, Rhinosinusitis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Young Elite Scientists Sponsorship Program by CAST, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
The therapeutic outcomes of patients with eosinophilic chronic rhinosinusitis (ECRS) remain unsatisfactory, largely because the underlying mechanisms of eosinophilic inflammation are uncertain. Here, it is shown that the nasal secretions of ECRS patients have high eosinophil extracellular trap (EET) and cell‐free DNA (cfDNA) levels. Moreover, the cfDNA induced EET formation by activating toll‐like receptor 9 (TLR9) signaling. After demonstrating that DNase I reduced eosinophilic inflammation by modulating EET formation, linear polyglycerol‐amine (LPG A )‐coated TiS 2 nanosheets (TLPG A ) as functional 2D nanoplatforms with low cytotoxicity, mild protein adsorption, and increased degradation rate is developed. Due to the more flexible linear architecture, TLPG A exhibited higher cfDNA affinity than the TiS 2 nanosheets coated with dendritic polyglycerol‐amine (TDPG A ). TLPG A reduced cfDNA levels in the nasal secretions of ECRS patients while suppressing cfDNA‐induced TLR9 activation and EET formation in vitro. TLPG A displayed exceptional biocompatibility, preferential nasal localization, and potent inflammation modulation in mice with eosinophilic inflammation. These results highlight the pivotal feature of the linear molecular architecture and 2D sheet‐like nanostructure in the development of anti‐inflammation nanoplatforms, which can be exploited for ECRS treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, China.
- Department of Otolaryngology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, China.
- Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, China.
- Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, China.
- ENT institute, Eye & ENT Hospital, Fudan University, Shanghai, 201114, China.
ORCID-Profile: Zhaoxu Tu
Förderung
- National Natural Science Foundation of China
- Young Elite Scientists Sponsorship Program by CAST
- Natural Science Foundation of Guangdong Province
- China Postdoctoral Science Foundation
Zitieren
APA
Tu, Z., Liu, M., Xu, C., Wei, Y., Lu, T., Xiao, Y., Li, H., Zhang, S., Xie, X., Li, J., & Wen, W. (2024). Functional 2D Nanoplatforms Alleviate Eosinophilic Chronic Rhinosinusitis by Modulating Eosinophil Extracellular Trap Formation. Advanced Science. https://doi.org/10.1002/advs.202307800
Vancouver
Tu Z, Liu M, Xu C, Wei Y, Lu T, Xiao Y, et al. Functional 2D Nanoplatforms Alleviate Eosinophilic Chronic Rhinosinusitis by Modulating Eosinophil Extracellular Trap Formation. Advanced Science. 2024. doi:10.1002/advs.202307800
BibTeX
@article{Tu2024,
author = {Tu, Zhaoxu and Liu, Ming and Xu, Changyi and Wei, Yi and Lu, Tong and Xiao, Yongqiang and Li, Hongxia and Zhang, Shuaiyin and Xie, Xinran and Li, Jian and Wen, Weiping},
title = {Functional 2D Nanoplatforms Alleviate Eosinophilic Chronic Rhinosinusitis by Modulating Eosinophil Extracellular Trap Formation},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202307800}
}
EUVIMED